Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any isolated trigonocephaly in which the cause of the disease is a mutation in the FGFR1 gene.
Features include always present findings: Epicanthus, Upslanted palpebral fissure, Wide nasal bridge, and Long philtrum and others. 19 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Head and neck | 3 | Microcephaly, Craniosynostosis, High, narrow palate |
FGFR1 encodes fibroblast growth factor receptor 1 (822 aa). Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of embryonic development, cell proliferation, differentiation and migration. Highest expression in Artery Aorta (144.8 TPM) and Ovary (142.9 TPM).
Trigonocephaly 1 is associated with mutations in the FGFR1 gene on chromosome 8.
The FGFR1 protein participates in p-8Y- FGFR1 R576W, p-8Y-FGFR1 N546K, and p-8Y-FGFR1 K656E pathways.
FGFR1 is classified as a druggable target (Clinically Actionable, Drug Resistance, Druggable Genome, Kinase, and Tyrosine Kinase categories) with score 1.1.
Clinical diagnostic criteria for encephalocraniocutaneous lipomatosis (ECCL) have been published and are adapted below based on the recent literature .
ECCL should be suspected in individuals with at least one major criterion in each of two different systems or in individuals with a biopsy-proven or possible nevus psiloliparus (NP), and one minor criterion in a second (non-skin) system (for clinical diagnostic criteria, see ).
Major Criteria
Skin
No approved treatments are currently available for trigonocephaly 1. The disease remains an area of unmet medical need.
No clinical practice guidelines for encephalocraniocutaneous lipomatosis (ECCL) have been published. Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with ECCL, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 6. Recommended Evaluations Following Initial Diagnosis in Individuals with Encephalocraniocutaneous Lipomatosis
Table 8. Recommended Surveillance for Individuals with Encephalocraniocutaneous Lipomatosis
System/Concern |
|---|
No clinical trials have been registered for trigonocephaly 1.
43 publications have been identified in PubMed for trigonocephaly 1. Research spans Clinical Trial Publication (28%), Epidemiology / Natural History (23%), and Case Report / Case Series (16%).
Research Type | Count | % of Total |
|---|---|---|
Clinical study results | 12 | 28% |
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 1:53 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
2 |
Delayed speech and language development, Intellectual disability |
Skin | 1 | Preauricular skin tag |
Age of onset: at birth.
To date, at least 85 individuals with a clinical and/or molecular diagnosis of encephalocraniocutaneous lipomatosis (ECCL) have been reported [, , , ]. Of these, 14 individuals have been identified with a pathogenic variant in FGFR1 [, , , , , ] and a few with a pathogenic variant in KRAS [, , , ]. The following description of the phenotypic features in individuals with a clinical and/or molecular diagnosis associated with ECCL is based on these reports. Note: There is evidence that oculoectodermal syndrome (OES) may constitute a clinical spectrum with ECCL, with OES on the mild end and ECCL on the more severe end of the spectrum. Individuals who do not fulfill the clinical diagnostic criteria for ECCL but display some features have sometimes been reported as having OES . ECCL comprises a spectrum of predominantly congenital anomalies. In its typical form, ECCL is characterized by congenital skin, eye, and brain anomalies, in particular intracranial and spinal lipomas. To a much lesser degree, the bones and the heart can be affected. About 40% of affected individuals have bilateral abnormalities of the skin or the eyes. Although variable in its extent and severity, the pattern of skin and eye findings is often consistent and recognizable. Since 2016, ECCL has also been recognized as a tumor predisposition syndrome . Table 2. Encephalocraniocutaneous Lipomatosis: Frequency of Select Features
Feature | % of Personsw/Feature | Comment |
|---|---|---|
Skin | Nevus psiloliparus | 75% |
Nodular skin tags | 70%-75% | Periocular or between outer canthus tragus |
Alopecia | Common | A specific percentage is difficult to define. |
Subcutaneous fatty lipomas | 40% | Frontotemporal or zygomatic |
Focal scalp aplasia/hypoplasia | 25% | — |
Pigmentary abnormalities | Rare | Either as spots or following lines of Blaschko |
Eye | Choristomas | 80%-85% |
CNS | Intracranial lipomas | 65% |
Other findings | Common | See . |
Neurologic | Developmental delay/intellectual disability | 65% |
Seizures | 50% | — |
Tumors | Brain tumors | Unknown |
Jaw tumors | Unknown | Based on , , Skin. Non-scarring alopecia (with or without underlying fatty tissue) and subcutaneous fatty masses are the most typical skin anomalies. |
Source: GeneReviews — "Encephalocraniocutaneous Lipomatosis"
To date, all individuals with molecularly confirmed ECCL have had mosaicism for one of a few known gain-of-function pathogenic variants in either FGFR1 or KRAS (see , , and ).
Source: GeneReviews — "Encephalocraniocutaneous Lipomatosis"
Biopsy-proven nevus psiloliparus (NP)
Possible NP in addition to one or more of the other minor skin criteria listed below
Two or more minor skin criteria listed
Eye. Choristoma (e.g., epibulbar dermoid)
Central nervous system (CNS)
Source: GeneReviews — "Encephalocraniocutaneous Lipomatosis"
The differential diagnosis of encephalocraniocutaneous lipomatosis (ECCL) also includes other mosaic RASopathies (a group of syndromes caused by mosaic mutations of the Ras/MAPK signaling pathway ):
Source: GeneReviews — "Encephalocraniocutaneous Lipomatosis"
Genetic testing for FGFR1 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for trigonocephaly 1 has been reported in the published literature.
System/Concern | Evaluation | Comment |
|---|---|---|
Skin | Full skin exam | For evidence of nevus psiloliparus, subcutaneous fatty lipomas, cutis aplasia, alopecia, pigmentary anomalies |
Eye | Ophthalmologic exam | Assess for evidence of choristoma, or any other eye anomaly. |
CNS | Neurologic exam | Brain spinal MRI/MRA |
Development | Developmental assessment | To incl motor, adaptive, cognitive, speech-language eval; Eval for early intervention/ special education |
Musculoskeletal | Consider a skeletal survey. | To assess for osteomas, ossifiying fibromas, lytic bone lesions Dental |
involvement | Exam by pediatric or adult dentist, depending on age | Assess for odontomas.; Further imaging of jaw for jaw tumors may be considered. |
Genitourinary | Consider baseline renal ultrasound in persons up to age 8 yrs. | Only in those who have a KRAS pathogenic variant that involves codon 12 Genetic |
counseling | By genetics professionals1 | To inform affected persons their families re nature, MOI, implications of ECCL to facilitate medical personal decision making Family support resources |
Treatment of Manifestations in Individuals with Encephalocraniocutaneous Lipomatosis Manifestation/Concern | Treatment | Considerations/Other NP, alopecia, focal skin aplasia/hypoplasia, |
nodular skin tags | Standard treatment per dermatologist | Many skin findings do not require active mgmt. Choristomas/ Eye |
anomalies | Standard treatment per ophthalmologist | Community vision services through early intervention or school district for those w/significant visual impairment |
Epilepsy | Standardized treatment w/ASM by experienced neurologist | Many ASMs may be effective; none has been demonstrated effective specifically for this disorder.; Education of parents/caregivers1 |
Low-grade gliomas | Standard treatment per oncologist/neuro-oncologist | 1 person w/FGFR1-related ECCL a progressive pilocytic astrocytoma was treated w/trametinib (a MEK inhibitor) w/resultant stable tumor size after 6 mos of treatment.2 |
DD/ID | See . | — |
Lytic bone lesions | Standard treatment per orthopedist, if needed | — |
Jaw tumors | Standard treatment per dentist | Such tumors are not typically malignant but can grow into surrounding tissues. |
Wilms tumor | Standard treatment per oncologist | It is currently unclear if persons w/ECCL are at risk for development of Wilms tumor.; See also Wilms Tumor Predisposition. Family support resources |
Source: GeneReviews — "Encephalocraniocutaneous Lipomatosis"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Encephalocraniocutaneous Lipomatosis"
View trials for trigonocephaly 1
Evaluation
Frequency |
|---|
Neurologic | Consider brain MRI to screen for brain tumors.1 | Typically annually,2 or as clinically indicated Monitor those w/seizures as clinically indicated. |
Eye | Ophthalmologic eval | Annually in childhood adolescence or as clinically indicated |
Dental | Dental eval | At least every 6 mos |
Genitourinary | Renal ultrasound | Consider every 3 mos until age 8 yrs in those w/a KRAS pathogenic variant involving codon 12.3 Miscellaneous/ |
Other | Assess family need for social work support (e.g., palliative/respite care, home nursing, other local resources) care coordination. | At each visit 1. Brain tumors have not been reported in individuals with KRAS-related ECCL. Unless the affected individuals have molecularly confirmed KRAS-related ECCL, in which case brain MRI should be performed based on clinical signs and symptoms. |
Source: GeneReviews — "Encephalocraniocutaneous Lipomatosis"
Phenotype severity distribution: 10 always present features.
10 |
23% |
Patient case studies | 7 | 16% |
Research summaries | 5 | 12% |
Testing and diagnosis research | 3 | 7% |
Laboratory research | 3 | 7% |
Other research | 2 | 5% |
New treatment approaches | 1 | 2% |
Saad R (2026). [PMID: 40843924](https://pubmed.ncbi.nlm.nih.gov/40843924/). *Am J Med Genet A*. [Case Report / Case Series]
Elshafie RM (2026). [PMID: 41312766](https://pubmed.ncbi.nlm.nih.gov/41312766/). *Am J Med Genet A*. [Case Report / Case Series]
Park RK (2026). [PMID: 41637834](https://pubmed.ncbi.nlm.nih.gov/41637834/). *Int J Pediatr Otorhinolaryngol*. [Epidemiology / Natural History]
Bashawieh OO (2026). [PMID: 41604010](https://pubmed.ncbi.nlm.nih.gov/41604010/). *Childs Nerv Syst*. [Epidemiology / Natural History]
Davalan W (2026). [PMID: 41173227](https://pubmed.ncbi.nlm.nih.gov/41173227/). *Exp Neurol*. [Review / Meta-Analysis]
Suraj Prasad A (2026). [PMID: 39422444](https://pubmed.ncbi.nlm.nih.gov/39422444/). *Br J Neurosurg*. [Epidemiology / Natural History]
Lange E (2026). [PMID: 41167306](https://pubmed.ncbi.nlm.nih.gov/41167306/). *J Stomatol Oral Maxillofac Surg*. [Clinical Trial Publication]
Guillen Arguello R (2026). [PMID: 40693761](https://pubmed.ncbi.nlm.nih.gov/40693761/). *Oper Neurosurg*. [Clinical Trial Publication]
Frejlich M (2026). [PMID: 40739742](https://pubmed.ncbi.nlm.nih.gov/40739742/). *Vet Ophthalmol*. [Epidemiology / Natural History]
Munarriz PM (2025). [PMID: 40214267](https://pubmed.ncbi.nlm.nih.gov/40214267/). *Neurosurgery*. [Other]